---
title: "Processa Pharmaceuticals (PCSA.US) — Financial Reports"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/PCSA.US/norm.md"
symbol: "PCSA.US"
name: "Processa Pharmaceuticals"
parent: "https://longbridge.com/en/quote/PCSA.US.md"
datetime: "2026-06-13T21:00:08.349Z"
locales:
  - [en](https://longbridge.com/en/quote/PCSA.US/norm.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/PCSA.US/norm.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/PCSA.US/norm.md)
---

# Processa Pharmaceuticals (PCSA.US) — Financial Reports

## Income Statement (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| EPS | -1.29 | -1.49 | -1.81 | -6.32 | -7.44 |
| ROE | -332.80% | -235.49% | -230.24% | -326.68% | -434.16% |
| Revenue | - | - | - | - | - |
| Net income | -3.38M | -3.36M | -3.44M | -3.93M | -2.83M |
| Operating income | -3.33M | -3.70M | -3.49M | -3.95M | -2.85M |
| Gross margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| Profit quality | - | - | - | - | - |

## Balance Sheet (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| A&L | 4.52M | 7.81M | 7.58M | 8.18M | 4.81M |
| Leverage | 1.78 | 1.40 | 1.30 | 1.34 | 1.36 |
| BVPS | 0.9489 | 2.17 | 2.76 | 3.79 | 16.73 |
| Turnover | - | - | - | - | - |
| Cash & STI | 1.69M | 5.54M | 6.31M | 6.94M | 2.90M |
| Inv & Rec | - | - | - | - | - |
| LT assets | 3511.00 | 3812.00 | 4113.00 | 28732.00 | 52452.00 |
| Net debt | -1.69M | -5.54M | -6.31M | -6.91M | -2.85M |

## Cash Flow Statement (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| Operating CF | -3.59M | -2.90M | -3.48M | -2.27M | -2.73M |
| Investing CF | -500000.00 | -850000.00 | - | - | - |
| Financing CF | 244783.00 | 2.98M | 2.86M | 6.31M | 4.44M |
| Free CF | -2.45M | -1.56M | -2.24M | -806387.00 | -1.96M |
| OCF coverage | - | - | -92866.84% | -172785.77% | -177724.48% |
| Repaid & issued | - | - | - | - | - |
| CapEx | - | - | - | - | - |